Hinai Adil A, Valk Peter J M
Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Br J Haematol. 2016 Mar;172(6):870-8. doi: 10.1111/bjh.13898. Epub 2016 Jan 5.
Deregulated expression of the ecotropic virus integration site 1 (EVI1) gene is the molecular hallmark of therapy-resistant myeloid malignancies bearing chromosomal inv(3)(q21q26·2) or t(3;3)(q21;q26·2) [hereafter referred to as inv(3)/t(3;3)] abnormalities. EVI1 is a haematopoietic stemness and transcription factor with chromatin remodelling activity. Interestingly, the EVI1 gene also shows overexpression in 6-11% of adult acute myeloid leukaemia (AML) cases that do not carry any 3q aberrations. Deregulated expression of EVI1 is strongly associated with monosomy 7 and 11q23 abnormalities, which are known to be associated with poor response to treatment. However, EVI1 overexpression has been revealed as an important independent adverse prognostic marker in adult AML and defines distinct risk categories in 11q23-rearranged AML. Recently, important progress has been made in the delineation of the mechanism by which EVI1 becomes deregulated in inv(3)/t(3;3) as well as the cooperating mutations in this specific subset of AML with dismal prognosis.
嗜异性病毒整合位点1(EVI1)基因的异常表达是携带染色体inv(3)(q21q26·2)或t(3;3)(q21;q26·2)(以下简称inv(3)/t(3;3))异常的治疗抵抗性髓系恶性肿瘤的分子标志。EVI1是一种具有染色质重塑活性的造血干性和转录因子。有趣的是,EVI1基因在6%-11%不携带任何3q畸变的成人急性髓系白血病(AML)病例中也表现出过表达。EVI1的异常表达与7号染色体单体和11q23异常密切相关,已知这些异常与治疗反应不佳有关。然而,EVI1过表达已被揭示为成人AML中一个重要的独立不良预后标志物,并在11q23重排的AML中定义了不同的风险类别。最近,在阐明EVI1在inv(3)/t(3;3)中异常表达的机制以及这种预后不良的AML特定亚组中的协同突变方面取得了重要进展。